- Dose range
- 2 mg/day
- Route
- Subcutaneous injection, daily
- Indication(s)
- HIV-associated lipodystrophy (FDA approved 2010); visceral fat
Titration schedule
| Step | Dose | Duration | Notes |
|---|---|---|---|
| - | 2 mg | Daily | FDA-approved for HIV lipodystrophy |
Important notes
- This research compound dosing chart is intended as a reference for clinicians and patients reviewing protocols, not a substitute for individualized prescriber guidance.
- Research compound; not FDA-approved for any indication. Off-label or experimental use only.
- Compounded versions, where applicable, must be prepared by a licensed 503A or 503B compounding pharmacy. The April 14, 2026 FDA action restricted salt-form active ingredients.
References
- Tesamorelin (FDA-approved) prescribing information / clinical literature.
- FDA Section 503A Interim Bulk Drug Substances List, updated April 14, 2026.
- USP <797>: Pharmaceutical Compounding — Sterile Preparations.